Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Radiopharm Theranostics’ RAD 101 imaging molecule identified brain tumours in all 12 treatment-naïve patients in a ...

Regeneron has reported positive outcomes from the Phase III trial of Eylea HD in treating individuals with macular oedema ...

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

Lilly has revealed that subjects with Crohn's disease have achieved long-term clinical and endoscopic outcomes with Omvoh in the VIVID-2.

Annovis Bio has commenced the treatment of subjects in a Phase III clinical trial of buntanetap in treating early Alzheimer's ...

The partnership between the US military and the body and the non-profit will examine three drugs as potential therapies ...

Early detection and public health interventions are critical in improving sepsis survival rates and limiting its long-term ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

Qlaris Bio has reported positive topline outcomes from two Phase II US trials of QLS 111 in individuals with POAG and OHT.

A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...